patients had no further relapses at all. Thus, for these patients, who had previously been severely ill and therapy-resistant, high-dose T4 administration proved to have excellent effects on the course of the illness. However, in five of these patients the effect of the T4 was strong enough only when it was administered in combination with a prophylactic and antidepressant and/or neuroleptic drug, of which in some cases high doses were also needed. The side effects were negligible. Mechanisms that may possibly underlie the beneficial effects of high-dose T4 in bipolar affective disorder are discussed. [Neuropsychopharmacology 10:183-189, 1994J tients (Prange et al. 1969 (Prange et al. , 1970 (Prange et al. , 1972 . However, the beneficial effects of TRH and T3 supplementation of cur rent antidepressant medication or in treatment-resistant patients remain controversial to date. In regard to the efficacy of T3, in particular, both beneficial (e.g., Good win et Joffe and Singer 1990 ) and negative results (e.g., Feighner et al. 1972 , Gitlin et al. 1987 , see Stein and Avne 1988 for a review) have been reported.
During the past decade three reports have been published that describe beneficial effects of treatment with high, supraphysiological doses of thyroxine (T4) in previously treatment-resistant, rapid-cycling, bipo lar affective illness. Stancer and Persad (1982) reported that rapid cycling ceased in five out of eight women, but did not in two men, following treatment with up to 500 Ilg T4 per day. Leibow (1983) reported on the case of a rapid-cycling woman who responded well to 400 Ilg thyroxine per day. Finally, published impressive results of treatment with high-dose T4 (150 to 400 Ilg/day) in patients with rapid-0893-133X/94/$7.00 cycling affective illness who had previously failed to re spond to any treatment.
All of these studies intentionally included rapid cycling, bipolar patients only. As rapid cycling affects only approximately 10 to 15% of all bipolar patients (e.g., Dunner and Fieve 1974) , which in turn is only a small minority of patients with affective illness, we were interested in investigating whether administration of high-dose T4 would also be effective in treatment resistant, non-rapid cycling, bipolar patients. Here we report the initial results of an ongoing open trial of high dose T4 treatment in six previously treatment-resistant, very severely ill bipolar patients. The results for the rust 4 years of the trial (1989) (1990) (1991) (1992) (1993) are given.
PATIENTS AND METHODS
The patients were accepted for the study on the basis of both their diagnosis and their clinical course. They were required to meet DSM-ITI-R criteria for major aff ec tive disorder, bipolar subtype. However, patients ful filling the criteria established by Dunner and Fieve (1974) for rapid cycling (i.e., four or more affective episodes within the 12 months immediately preceding evaluation) were not accepted. As little experience has been gained to date with long-term treatment of depressed patients with supraphysiological doses of T4, we could not rule out the possibility that side effects might occur and that they might even be severe, par ticularly during chronic treatment. For ethical reasons we therefore deliberately selected only patients who had been resistant to all conventional medication and whose illness had taken a very severe course during the past few years. Thus, only patients who failed to respond to prophylactic treatment with lithium alone, carbamazepine alone, a combination of both, or a com bination of these prophylactic drugs with antidepres sants and/or neuroleptics were considered for inclusion in the study. A patient was classified as treatment resistant only if treatment with each of the above drugs or combinations of drugs had been unsuccessful for at least 6 months. Since 1989 a total of 11 patients have taken part in the study. In two cases high-dose T4 treat ment was not instituted until after July 1992; thus it is too early to assess the clinical efficacy of the treatment in these two patients. A further two patients were with drawn from the study because of non-compliance. They stopped taking both thyroxine and their other psy chotropic medication several times during the rust year of treatment, as they had also done during the period before beginning high-dose T4 treatment. A fIfth pa tient, who had delusional depression (bipolar II) broke her hip in a fall and was treated for this and other or ganic disorders in other hospitals, and thus it was not NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.3 possible to continue with the high-dose T4 treatment.
Therefore, a total of six patients finally took part in the study. Their clinical and sociodemographic data are shown in Table l .
Four of these patients were women and two were men, and their mean age was 52.8 years with a stan dard deviation of 11.8 and a range of 33 to 68 years.
All of them had major affective disorder, which was bipolar I subtype in four cases and bipolar II subtype in two. None of these patients fulfilled the DSM-III-R definition or the Dunner and Fieve criteria (Dunner and Fieve 1974) for rapid cycling (see Table 1 ). In none of the cases did the reasons for instituting high-dose T4 treatment constitute an attempt to handle a treatment resistant course of rapid-cycling major affective disor der, as was the case in all previous studies (Stancer and Persad 1982; Leibow 1983; .
The six patients were included in the study for the fol lowing reasons. Patients 1, 3, and 4 had repeated epi sodes of treatment-resistant depression. Their depres sive symptoms had repeatedly failed to respond to high doses of different antidepressants, with and without lithium and/or carbamazepine treatment. They some times responded to a series of electroconvulsive ther apy (ECT), but the depressive symptomatology regu larly returned after periods varying from some weeks or, at best, some months. As can be seen from Table   1 , during the 3-year period prior to the start of treat ment with T4 these patients were hospitalized for 3, 18, and 16 months, respectively. They were depressed for most of the time, and hypomanic episodes (e.g., af ter EC T treatment) were the exception. In these three patients the main purpose of administering high doses of T4 was therefore to prevent their most severe and resistant relapses into depression.
In contrast, patients 2, 5, and 6 also had severe manic episodes that always required hospitalization on a locked ward and had been involved several times in conflicts with the police or other institutions. The symp tomatologies of patients 2 and 6 were predominantly manic, with only short depressive episodes of minor severity. All prophylactic agents (lithium, carbamaze pine, valproate [in two patients] and neuroleptics) failed to prevent further manic episodes in these patients.
Over a period of several years this severe course of the illness had led to severe impairment of the social and working lives of all of these patients. For these reasons we instituted high-dose T4 treatment in an attempt to prevent further severe manic episodes. None of the pa tients had a history of alcohol or drug abuse or was cur rently addicted to any substance. However, the four women had histories of subclinical hypothyroidism and/or Hashimoto's thyroiditis (patients 1 through 4, Table 1 ). In three of these women, the thyroid disorder clearly preceded the initiation of lithium treatment, and The efficacy of high-dose T4 treatment was evalu ated as follows. An "episode" or a "relapse" was defIned as a change in a patient's affective state that required either changes in medication on an outpatient basis (e.g., increases in the doses of the drugs taken), a change to new drugs, or hospitalization. Furthermore, the total time (in months) spent in hospital following institution of high-dose T4 administration was com pared to the time spent in hospital before the high-dose prophylaxis was begun, separately for each patient (i.e., when we were able to follow a patient on high-dose T4 for 36 months [e.g., patient I, Table 2 ], we compared the duration of hospitalization during these 36 months with that during the 36 months prior to institution of the high-dose T4 treatment).
During a relapse all patients were rated weekly on the Bech-Rafaelsen Scale. When not in hospital, the pa cases. The concentrations of TSH and thyroid hormone (T 4, IT 4, T3, and IT3) were determined at least once ev ery 6 weeks during euthymic phases and once a week during relapses. The hormone determinations were car ried out as previously described with IRMA (for TSH), RIA (T4 and T3) and RIA-Dynotest (for IT3 and fT4
respectively) (Baumgartner et al. 1988) . Kits from Hen ning, Berlin were used throughout. All data are given as means ± standard deviations.
RESULTS
The mean follow-up time for all six patients was 27.8 ± 12.8 months (range 12 to 46 months) ( Table 2 ). Dur ing this period the mean number of relapses was 0.8 ± 0.8 (range 0 to 2) as compared to 5.3 ± 3.1 (range 1 to 9) in the respective periods prior to institution of high-dose T4 treatment ( Table 2) . Four of the patients were able to stay out of hospital completely during the high-dose T4 treatment and two others were readmit ted for a total of 2 and 3 months respectively (see be low). Table 2 shows that the mean time spent in hospi tal was reduced from 10.0 ± 5.6 months (range 6 to 20 � months) before T4 treatment to 0.8 ± 1.2 months (range +I to 500 mg/day again. Thus, the two relapses of this pa-:;:; tient (see Table 2 ) were obviously related to a reduction of the neuroleptic dose .
The relevance of concomitant psychotropic medi-6 cation for patient 3 is particularly well documented. This +I patient had two brief depressive relapses even after she 6 had already been taking 500 J.lg T4/day for several months. At the time of the fIrst relapse she was also 00 taking 100 mg imipramine/day. This dose was increased � to 150 mg/day during a stay in hospital. Following dis +I charge from hospital and some months during which 00 t--:
she was euthyrnic, she had a further relapse into depres-N sion, which again required hospitalization. This time the dose of imipramine was increased to 300 J.lg/day, lii and since then she has had no further depressive epi � sodes. Note that it was possible to successfully treat the two episodes of depression that occurred during high dose T4 treatment within one month in each case, whereas before high-dose T4 supplementation the av erage duration of hospitalization required to treat this patient's depressive episodes was about 5 to 6 months.
We tried twice to withdraw concomitant low-dose (50 to 100 mg/kg) clozapine medication in this patient.
Both times she reported sleep disturbances beginning on the night immediately after clozapine withdrawal and felt that she was in danger of developing manic symptoms. Therefore, after two days the clozapine was reinstituted on both occasions.
Finally, we realized that patient 4 needed at least 40 mg/ day fluoxetine in order to prevent depressive relapses and patient 6 developed hypomanic symptoms when we tried to reduce his clozapine dose from 200 mg/day.
In summary, only patient 1 has remained on T4 alone (250 Ilg/day) without further relapses for a total of exactly 3 years. In fact, our subjective impression was that she began to feel really well only after the lithium, carbamazepine and, fInally, valproate had been with drawn.
For all serum levels of thyroid hormones we calcu raised the TSH levels were not suppressed.
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Thus, almost all the thyroid hormone and TSH con centrations before initiation of high-dose T4 treatment were well within the normal range in all patients. How ever, the three patients who had not been given thyrox ine before the start of the study (patients 4 through 6) had thyroid hormone concentrations at or even below the lower limit of the normal range in several of the numerous laboratory tests performed (full data not shown). These three patients repeatedly had T4 levels below 40 Ilg/L and T3 levels below 0.8 Ilg/L without any corresponding changes in TSH concentrations.
The side effects were negligible. Two patients com plained of continuous mild sweating, and patient 4 had mild tachycardia (80 to 90 beats/min). The remaining four patients did not report any side effects that could have been related to the high-dose thyroxine treatment.
DISCUSSION
In our opinion, treatment of these very seriously ill and previously treatment-resistant patients with supra physiological doses of thyroxine proved highly success ful. After final adjustment of the doses of both T4 and the concomitant medication our patients had no fur ther relapses. This leads us to conclude that-in addi tion to the treatment of refractory rapid-cycling bipolar patients-high-dose T4 supplementation may also be justifIed in severely treatment-and prophylaxis resistant, non-rapid cycling bipolar patients.
Both the experience gained in other previous studies (Stancer and Persad 1982; and our own results strongly suggest that supraphysio logical levels of T4 should be given and supraphysio logical serum concentrations of thyroid hormone at tained in these patients. The fact that three of our patients (1 through 3) had already been receiving sub stitution therapy with physiological doses of T4 before we started them on supraphysiological doses and still suffered from treatment-resistant affective episodes strongly supports this conclusion.
As already suggested by we also believe that in the majority of cases high-dose from the circulation but is almost entirely derived from intracellular deiodination ofT4 (e.g., Crantz et al. 1982) .
Thus, the T4 supply to the CNS depends heavily on the serum levels of T 4, and not on those of T3. Further more, we recently found that antidepressants such as desipramine (Baumgartner et a1. 1990; ) and fluoxetine , and also lithium and carbamazepine (Baumgartner et al., manuscript in preparation) It is striking that all four of the women in our study, but not the two men, had a history of subclinical hypo thyroidism and/or Hashimoto's thyroiditis. In at least three of them, the thyroid disorder clearly preceded the lithium treatment. There are numerous reports in the literature of an abnormally high incidence of subclini cal hypothyroidism in rapid-cycling bipolar patients, but the results are contradictory (e.g., Wehr et al. 1988) . Joffe et a1. (1988) also investigated a group of non-rapid cycling bipolar patients and found that the incidence (19%) of subclinical hypothyroidism in this subgroup was related to female sex and the du ration of lithium treatment rather than to the diagnosis per se. In this regard it would seem interesting that Stancer and Persad (1982) reported that high-dose T4 treatment is effective only in rapid-cycling women, and not rapid-cycling men. In contrast, in our population, both men and women responded equally well.
Finally, it is interesting that our patients complained hardly at all of side effects, although their serum con centrations of thyroid hormone were in the supraphysi ological range. It would therefore seem justified to ask whether these patients were suffering from a distur bance of some step between T4 secretion and T3 recep tor effects.
